RFP
SPRY icon

Root Financial Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Root Financial Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58
Closed -$466 – 2786
2026
Q1 		$466 Buy
+58
New +$556 ﹤0.01% 2888

Other funds holding SPRY

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Root Financial Partners's SPRY Position: Q2 2026 in Review

Root Financial Partners sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 58 shares — an estimated $466 sold.

Root Financial Partners first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $466 in Q1 2026. 29 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Root Financial Partners reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 58 ARS Pharmaceuticals shares in Q2 2026, an estimated $466.
  • Root Financial Partners first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's ARS Pharmaceuticals position peaked at $466 in Q1 2026.
  • 29 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.